/
Infectious Disease
COVID-19
1.5K
Pipeline Programs↗
138
Active Trials↗
333
Companies Involved↗
COVID-19 is a highly competitive landscape with 1463 programs across 333 companies. The most active players are GSK, Biogen, Moderna. 159 therapies are approved with 404 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical190
Phase 1192
Phase 2518
Phase 3404
Analysis
Modality Breakdown
76%
Small molecule
1,115 of 1,476 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 1,476 classified programs, each share of the total. Modality classified for 99% of 1,948 pipeline programs.
Analysis
Trial Status
2,712
clinical trials
Completed1,285 · 47%
Unknown status654 · 24%
Terminated369 · 14%
Withdrawn217 · 8%
Active, not recruiting58 · 2%
Recruiting55 · 2%
Other74 · 3%
Clinical Trials
Trial Activity
2712 trials
Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment
Recruiting·—·Phase 2·NCT06159283·58 enrolled
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT06599658·660 enrolled
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
Recruiting·—·Phase 2·NCT07406217·256 enrolled
Page 1 of 181
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)